Breda, the Netherlands / Ghent, Belgium, August 24, 2017 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatm [...]
- anti-ApoC3 antibody developed as part of research collaboration with Staten Biotechnology -
- Stems from argenx's Innovative Access Program -
Breda, the Netherlands / Ghent, Belgium, August 23, 20 [...]
UTRECHT, The Netherlands, July 28, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that [...]
Amsterdam-Duivendrecht, The Netherlands, July 26, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing in [...]
Amsterdam, the Netherlands - 20 July 2017 - LSP (Life Sciences Partners) announces its investment in Simplify Medical. Simplify Medical is focused on cervical spinal disc arthroplasty, using innovative, MRI-friendly m [...]
Balance sheet strengthened with $120 million upfront payment and an $80 million share purchase from Incyte Corporation for global strategic research collaboration to discover and develop bispecific antibodies
[...]
Breda, the Netherlands / Ghent, Belgium, July 7, 2017 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]
First patients enrolled in a multinational Phase 3 clinical trial of dasiglucagon
Dasiglucagon is a potential first-in-class glucagon analog suitable for a ready-to-use rescue pen to treat severe hypoglycemi [...]
TriMix-MEL (ECI-003), a rationally designed mRNA immunotherapy based on the unique TriMix platform, starts Phase Ib trial in adjuvant melanoma patients
Niel (Belgium), 30 June 2017 – eTheRNA immunotherapi [...]
Breda, the Netherlands / Ghent, Belgium, August 24, 2017 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatm [...]
- anti-ApoC3 antibody developed as part of research collaboration with Staten Biotechnology -
- Stems from argenx's Innovative Access Program -
Breda, the Netherlands / Ghent, Belgium, August 23, 20 [...]
UTRECHT, The Netherlands, July 28, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that [...]
Amsterdam-Duivendrecht, The Netherlands, July 26, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing in [...]
Amsterdam, the Netherlands - 20 July 2017 - LSP (Life Sciences Partners) announces its investment in Simplify Medical. Simplify Medical is focused on cervical spinal disc arthroplasty, using innovative, MRI-friendly m [...]
Balance sheet strengthened with $120 million upfront payment and an $80 million share purchase from Incyte Corporation for global strategic research collaboration to discover and develop bispecific antibodies
[...]
Breda, the Netherlands / Ghent, Belgium, July 7, 2017 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]
First patients enrolled in a multinational Phase 3 clinical trial of dasiglucagon
Dasiglucagon is a potential first-in-class glucagon analog suitable for a ready-to-use rescue pen to treat severe hypoglycemi [...]
TriMix-MEL (ECI-003), a rationally designed mRNA immunotherapy based on the unique TriMix platform, starts Phase Ib trial in adjuvant melanoma patients
Niel (Belgium), 30 June 2017 – eTheRNA immunotherapi [...]
Follow us
